Global Late Stage Chronic Kidney Disease Drugs Market Size, Status and Forecast 2020-2026

August 2020 | 94 pages | ID: G4D16B54E1C9EN
QYResearch

Abstracts

This report focuses on the global Late Stage Chronic Kidney Disease Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Late Stage Chronic Kidney Disease Drugs development in North America, Europe and Asia-Pacific.
The key players covered in this study

• AbbVie
• Amgen
• Ardelyx
• AstraZeneca
• Deltanoid
• Akebia Therapeutics
• Kyowa Hakko Kirin
• OPKO Health
• Vifor Pharma
• Sanofi
• Shield Therapeutics
• Shire
• Spectrum
• ZS Pharma

Market segment by Type, the product can be split into

• Calcimimetics
• Vitamin D Sterols
• Potassium Binders
• Others

Market segment by Application, split into

• Hospital Pharmacies
• Online Pharnacies
• Retail Pharmacies

Market segment by Regions/Countries, this report covers

• North America
• Europe
• Asia-Pacific

The study objectives of this report are:

• To analyze global Late Stage Chronic Kidney Disease Drugs status, future forecast, growth opportunity, key market and key players.
• To present the Late Stage Chronic Kidney Disease Drugs development in North America, Europe and Asia-Pacific.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Late Stage Chronic Kidney Disease Drugs are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Late Stage Chronic Kidney Disease Drugs Revenue
1.4 Market Analysis by Type
  1.4.1 Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Calcimimetics
  1.4.3 Vitamin D Sterols
  1.4.4 Potassium Binders
  1.4.5 Others
1.5 Market by Application
  1.5.1 Global Late Stage Chronic Kidney Disease Drugs Market Share by Application: 2020 VS 2026
  1.5.2 Hospital Pharmacies
  1.5.3 Online Pharnacies
  1.5.4 Retail Pharmacies
1.6 Coronavirus Disease 2019 (Covid-19): Late Stage Chronic Kidney Disease Drugs Industry Impact
  1.6.1 How the Covid-19 is Affecting the Late Stage Chronic Kidney Disease Drugs Industry
    1.6.1.1 Late Stage Chronic Kidney Disease Drugs Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Late Stage Chronic Kidney Disease Drugs Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Late Stage Chronic Kidney Disease Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Late Stage Chronic Kidney Disease Drugs Market Perspective (2015-2026)
2.2 Late Stage Chronic Kidney Disease Drugs Growth Trends by Regions
  2.2.1 Late Stage Chronic Kidney Disease Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Late Stage Chronic Kidney Disease Drugs Historic Market Share by Regions (2015-2020)
  2.2.3 Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Late Stage Chronic Kidney Disease Drugs Market Growth Strategy
  2.3.6 Primary Interviews with Key Late Stage Chronic Kidney Disease Drugs Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Market Size
  3.1.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue (2015-2020)
  3.1.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Players (2015-2020)
  3.1.3 Global Late Stage Chronic Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio
  3.2.1 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Late Stage Chronic Kidney Disease Drugs Revenue in 2019
3.3 Late Stage Chronic Kidney Disease Drugs Key Players Head office and Area Served
3.4 Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service
3.5 Date of Enter into Late Stage Chronic Kidney Disease Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Type (2015-2020)
4.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Type (2021-2026)

5 LATE STAGE CHRONIC KIDNEY DISEASE DRUGS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020)
5.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Late Stage Chronic Kidney Disease Drugs Market Size (2015-2020)
6.2 Late Stage Chronic Kidney Disease Drugs Key Players in North America (2019-2020)
6.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020)
6.4 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size (2015-2020)
7.2 Late Stage Chronic Kidney Disease Drugs Key Players in Europe (2019-2020)
7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020)
7.4 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020)

8 ASIA-PACIFIC

8.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size (2015-2020)
8.2 Late Stage Chronic Kidney Disease Drugs Key Players in Asia-Pacific (2019-2020)
8.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020)
8.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020)
(2015-2020)
(2015-2020)

9 KEY PLAYERS PROFILES

9.1 AbbVie
  9.1.1 AbbVie Company Details
  9.1.2 AbbVie Business Overview and Its Total Revenue
  9.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Introduction
  9.1.4 AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020))
  9.1.5 AbbVie Recent Development
9.2 Amgen
  9.2.1 Amgen Company Details
  9.2.2 Amgen Business Overview and Its Total Revenue
  9.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Introduction
  9.2.4 Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.2.5 Amgen Recent Development
9.3 Ardelyx
  9.3.1 Ardelyx Company Details
  9.3.2 Ardelyx Business Overview and Its Total Revenue
  9.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Introduction
  9.3.4 Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.3.5 Ardelyx Recent Development
9.4 AstraZeneca
  9.4.1 AstraZeneca Company Details
  9.4.2 AstraZeneca Business Overview and Its Total Revenue
  9.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Introduction
  9.4.4 AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.4.5 AstraZeneca Recent Development
9.5 Deltanoid
  9.5.1 Deltanoid Company Details
  9.5.2 Deltanoid Business Overview and Its Total Revenue
  9.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Introduction
  9.5.4 Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.5.5 Deltanoid Recent Development
9.6 Akebia Therapeutics
  9.6.1 Akebia Therapeutics Company Details
  9.6.2 Akebia Therapeutics Business Overview and Its Total Revenue
  9.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction
  9.6.4 Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.6.5 Akebia Therapeutics Recent Development
9.7 Kyowa Hakko Kirin
  9.7.1 Kyowa Hakko Kirin Company Details
  9.7.2 Kyowa Hakko Kirin Business Overview and Its Total Revenue
  9.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Introduction
  9.7.4 Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.7.5 Kyowa Hakko Kirin Recent Development
9.8 OPKO Health
  9.8.1 OPKO Health Company Details
  9.8.2 OPKO Health Business Overview and Its Total Revenue
  9.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Introduction
  9.8.4 OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.8.5 OPKO Health Recent Development
9.9 Vifor Pharma
  9.9.1 Vifor Pharma Company Details
  9.9.2 Vifor Pharma Business Overview and Its Total Revenue
  9.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Introduction
  9.9.4 Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.9.5 Vifor Pharma Recent Development
9.10 Sanofi
  9.10.1 Sanofi Company Details
  9.10.2 Sanofi Business Overview and Its Total Revenue
  9.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Introduction
  9.10.4 Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  9.10.5 Sanofi Recent Development
9.11 Shield Therapeutics
  10.11.1 Shield Therapeutics Company Details
  10.11.2 Shield Therapeutics Business Overview and Its Total Revenue
  10.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction
  10.11.4 Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  10.11.5 Shield Therapeutics Recent Development
9.12 Shire
  10.12.1 Shire Company Details
  10.12.2 Shire Business Overview and Its Total Revenue
  10.12.3 Shire Late Stage Chronic Kidney Disease Drugs Introduction
  10.12.4 Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  10.12.5 Shire Recent Development
9.13 Spectrum
  10.13.1 Spectrum Company Details
  10.13.2 Spectrum Business Overview and Its Total Revenue
  10.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Introduction
  10.13.4 Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  10.13.5 Spectrum Recent Development
9.14 ZS Pharma
  10.14.1 ZS Pharma Company Details
  10.14.2 ZS Pharma Business Overview and Its Total Revenue
  10.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Introduction
  10.14.4 ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
  10.14.5 ZS Pharma Recent Development

10 ANALYST'S VIEWPOINTS/CONCLUSIONS

11 APPENDIX

11.1 Research Methodology
  11.1.1 Methodology/Research Approach
  11.1.2 Data Source
11.2 Disclaimer
11.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Late Stage Chronic Kidney Disease Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Late Stage Chronic Kidney Disease Drugs Revenue
Table 3. Ranking of Global Top Late Stage Chronic Kidney Disease Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Calcimimetics
Table 6. Key Players of Vitamin D Sterols
Table 7. Key Players of Potassium Binders
Table 8. Key Players of Others
Table 9. COVID-19 Impact Global Market: (Four Late Stage Chronic Kidney Disease Drugs Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Late Stage Chronic Kidney Disease Drugs Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Late Stage Chronic Kidney Disease Drugs Players to Combat Covid-19 Impact
Table 14. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Late Stage Chronic Kidney Disease Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Late Stage Chronic Kidney Disease Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions (2015-2020)
Table 18. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Late Stage Chronic Kidney Disease Drugs Market Growth Strategy
Table 24. Main Points Interviewed from Key Late Stage Chronic Kidney Disease Drugs Players
Table 25. Global Late Stage Chronic Kidney Disease Drugs Revenue by Players (2015-2020) (Million US$)
Table 26. Global Late Stage Chronic Kidney Disease Drugs Market Share by Players (2015-2020)
Table 27. Global Top Late Stage Chronic Kidney Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2019)
Table 28. Global Late Stage Chronic Kidney Disease Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service
Table 31. Date of Enter into Late Stage Chronic Kidney Disease Drugs Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 34. Global Late Stage Chronic Kidney Disease Drugs Market Size Share by Type (2015-2020)
Table 35. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type (2021-2026)
Table 36. Global Late Stage Chronic Kidney Disease Drugs Market Size Share by Application (2015-2020)
Table 37. Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 38. Global Late Stage Chronic Kidney Disease Drugs Market Size Share by Application (2021-2026)
Table 39. North America Key Players Late Stage Chronic Kidney Disease Drugs Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Late Stage Chronic Kidney Disease Drugs Market Share (2019-2020)
Table 41. North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 42. North America Late Stage Chronic Kidney Disease Drugs Market Share by Type (2015-2020)
Table 43. North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 44. North America Late Stage Chronic Kidney Disease Drugs Market Share by Application (2015-2020)
Table 45. Europe Key Players Late Stage Chronic Kidney Disease Drugs Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Late Stage Chronic Kidney Disease Drugs Market Share (2019-2020)
Table 47. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Late Stage Chronic Kidney Disease Drugs Market Share by Type (2015-2020)
Table 49. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Late Stage Chronic Kidney Disease Drugs Market Share by Application (2015-2020)
Table 51. Asia-Pacific Key Players Late Stage Chronic Kidney Disease Drugs Revenue (2019-2020) (Million US$)
Table 52. Asia-Pacific Key Players Late Stage Chronic Kidney Disease Drugs Market Share (2019-2020)
Table 53. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2015-2020) (Million US$)
Table 54. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Share by Type (2015-2020)
Table 55. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2015-2020) (Million US$)
Table 56. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Share by Application (2015-2020)
Table 57. AbbVie Company Details
Table 58. AbbVie Business Overview
Table 59. AbbVie Product
Table 60. AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 61. AbbVie Recent Development
Table 62. Amgen Company Details
Table 63. Amgen Business Overview
Table 64. Amgen Product
Table 65. Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 66. Amgen Recent Development
Table 67. Ardelyx Company Details
Table 68. Ardelyx Business Overview
Table 69. Ardelyx Product
Table 70. Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 71. Ardelyx Recent Development
Table 72. AstraZeneca Company Details
Table 73. AstraZeneca Business Overview
Table 74. AstraZeneca Product
Table 75. AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 76. AstraZeneca Recent Development
Table 77. Deltanoid Company Details
Table 78. Deltanoid Business Overview
Table 79. Deltanoid Product
Table 80. Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 81. Deltanoid Recent Development
Table 82. Akebia Therapeutics Company Details
Table 83. Akebia Therapeutics Business Overview
Table 84. Akebia Therapeutics Product
Table 85. Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 86. Akebia Therapeutics Recent Development
Table 87. Kyowa Hakko Kirin Company Details
Table 88. Kyowa Hakko Kirin Business Overview
Table 89. Kyowa Hakko Kirin Product
Table 90. Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 91. Kyowa Hakko Kirin Recent Development
Table 92. OPKO Health Business Overview
Table 93. OPKO Health Product
Table 94. OPKO Health Company Details
Table 95. OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 96. OPKO Health Recent Development
Table 97. Vifor Pharma Company Details
Table 98. Vifor Pharma Business Overview
Table 99. Vifor Pharma Product
Table 100. Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 101. Vifor Pharma Recent Development
Table 102. Sanofi Company Details
Table 103. Sanofi Business Overview
Table 104. Sanofi Product
Table 105. Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 106. Sanofi Recent Development
Table 107. Shield Therapeutics Company Details
Table 108. Shield Therapeutics Business Overview
Table 109. Shield Therapeutics Product
Table 110. Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 111. Shield Therapeutics Recent Development
Table 112. Shire Company Details
Table 113. Shire Business Overview
Table 114. Shire Product
Table 115. Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 116. Shire Recent Development
Table 117. Spectrum Company Details
Table 118. Spectrum Business Overview
Table 119. Spectrum Product
Table 120. Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 121. Spectrum Recent Development
Table 122. ZS Pharma Company Details
Table 123. ZS Pharma Business Overview
Table 124. ZS Pharma Product
Table 125. ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2015-2020) (Million US$)
Table 126. ZS Pharma Recent Development
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Late Stage Chronic Kidney Disease Drugs Market Share by Type: 2020 VS 2026
Figure 2. Calcimimetics Features
Figure 3. Vitamin D Sterols Features
Figure 4. Potassium Binders Features
Figure 5. Others Features
Figure 6. Global Late Stage Chronic Kidney Disease Drugs Market Share by Application: 2020 VS 2026
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Online Pharnacies Case Studies
Figure 9. Retail Pharmacies Case Studies
Figure 10. Late Stage Chronic Kidney Disease Drugs Report Years Considered
Figure 11. Global Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions: 2020 VS 2026
Figure 13. Global Late Stage Chronic Kidney Disease Drugs Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Late Stage Chronic Kidney Disease Drugs Market Share by Players in 2019
Figure 16. Global Top Late Stage Chronic Kidney Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Late Stage Chronic Kidney Disease Drugs Revenue in 2019
Figure 18. North America Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 22. AbbVie Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 23. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 24. Amgen Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 25. Ardelyx Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Ardelyx Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 27. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. AstraZeneca Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 29. Deltanoid Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Deltanoid Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 31. Akebia Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Akebia Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 33. Kyowa Hakko Kirin Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Kyowa Hakko Kirin Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 35. OPKO Health Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. OPKO Health Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 37. Vifor Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Vifor Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 39. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Sanofi Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 41. Shield Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Shield Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 43. Shire Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Shire Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 45. Spectrum Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Spectrum Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 47. ZS Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. ZS Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2015-2020)
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed